Apogee Therapeutics Inc’s filing revealed that its Chief Medical Officer Dambkowski Carl unloaded Company’s shares for reported $48463.0 on Mar 05 ’25. In the deal valued at $30.48 per share,1,590 shares were sold. As a result of this transaction, Dambkowski Carl now holds 251,033 shares worth roughly $10.11 million.
Then, HENDERSON MICHAEL THOMAS sold 10,000 shares, generating $301,511 in total proceeds. Upon selling the shares at $30.15, the Chief Executive Officer now owns 1,292,987 shares.
Before that, HENDERSON MICHAEL THOMAS bought 10,000 shares. Apogee Therapeutics Inc shares valued at $301,501 were divested by the Officer at a price of $30.15 per share.
Canaccord Genuity initiated its Apogee Therapeutics Inc [APGE] rating to a Buy in a research note published on November 25, 2024; the price target was $89. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early May with a ‘”a Buy”‘ rating. BTIG Research began covering APGE with “Buy” recommendation on December 20, 2023. Wedbush started covering the stock on August 08, 2023. It rated APGE as “an Outperform”.
Price Performance Review of APGE
On Tuesday, Apogee Therapeutics Inc [NASDAQ:APGE] saw its stock jump 7.27% to $40.27. Over the last five days, the stock has gained 32.60%. Apogee Therapeutics Inc shares have fallen nearly -11.10% since the year began. Nevertheless, the stocks have fallen -38.27% over the past one year. While a 52-week high of $72.29 was reached on 01/07/25, a 52-week low of $29.10 was recorded on 03/04/25. SMA at 50 days reached $38.98, while 200 days put it at $46.01.
Levels Of Support And Resistance For APGE Stock
The 24-hour chart illustrates a support level at 37.05, which if violated will result in even more drops to 33.83. On the upside, there is a resistance level at 42.37. A further resistance level may holdings at 44.47. The Relative Strength Index (RSI) on the 14-day chart is 62.56, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.37, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 8.10%. Stochastics %K at 91.20% indicates the stock is a selling.
The most recent change occurred on August 08, 2023 when TD Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
